Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Metabolic Disorders Companies

BioMarin Adds Board Member

This article was originally published in Scrip

Executive Summary

BioMarin Pharmaceutical Inc. has appointed former chair and CEO of Allergan, David Pyott, to its board of directors. Pyott was CEO of Allergan from 1998 to 2015 and was recognized by the Harvard Business Review as one of 'The 100 Best Performing CEOs in the World'. Prior to Allergan he was the head of Novartis nutrition division and a member of the executive committee of Novartis AG. Currently Pyott is lead director and board member of Avery Dennison Corporation and a board member of Alnylam Pharmaceuticals Inc.

Table

View full table

Topics

Tags:
Metabolic Disorders Companies
Latest Headlines

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

AbbVie Claims Rinvoq Superiority To Dupixent In AD

Merck Investors Keeping A Close Watch On Winrevair Uptake

See All
UsernamePublicRestriction

Register

SC064129

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By